IPF Treatment RXC007 Shows Promise in Easing Scarring in Mice

IPF Treatment RXC007 Shows Promise in Easing Scarring in Mice

The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…

A Friend Gets an IPF Diagnosis, Then Sees It Taken Away

“While walking on the beach yesterday, I realized how I’m feeling about PF, in general, is like the tide. There are times like now that I’m riding the high tide, full of energy about taking on PF activities (hosting PF get-togethers, participating in fundraising walks). Then the water is gone,…

Piceatannol, Natural Compound, Seen to Ease PF Markers in Mice

Piceatannol, a natural compound with antioxidant and anti-inflammatory properties, eased the signs and symptoms of pulmonary fibrosis (PF) in mice, a study reported. According to its researchers, these findings indicate that piceatannol could be a promising treatment candidate for PF. The study, “Piceatannol-mediated JAK2/STAT3 signaling pathway inhibition…

Orphan Drug Status Sought for NP-120 to Treat IPF With Cough

Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…

Being Idiopathic: Solving the Mystery of My Diagnosis

I’ve spent much of my working life conducting investigations. As a special agent for the Air Force Office of Special Investigations and in a second career providing security and investigative services under contract to the federal government, the cases all had similar objectives. Simply stated, any investigation needs to answer…

Haduvio Greatly Reduces Coughing in IPF Patients in Phase 2 Trial

Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line data from the Phase 2 CANAL trial. “It is very promising to see such a significant reduction in chronic cough in IPF patients with [Haduvio],” Peter Dicpinigaitis, MD, a professor…